Genovis AB Share Price Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Sales 2024 * | 154M 14.61M 1.15B | Sales 2025 * | 189M 18.01M 1.42B | Capitalization | 1.96B 187M 14.73B |
---|---|---|---|---|---|
Net income 2024 * | 40M 3.81M 300M | Net income 2025 * | 49M 4.66M 368M | EV / Sales 2024 * | 12.1 x |
Net cash position 2024 * | 108M 10.3M 812M | Net cash position 2025 * | 128M 12.17M 959M | EV / Sales 2025 * | 9.7 x |
P/E ratio 2024 * |
48.5
x | P/E ratio 2025 * |
40.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 31/12/01 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 31/12/21 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 04/05/20 | |
Director/Board Member | 63 | 31/12/18 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 31/12/13 |
1st Jan change | Capi. | |
---|---|---|
-9.74% | 11.48B | |
-9.80% | 7.64B | |
+27.84% | 5.49B | |
-15.47% | 3.86B | |
+8.47% | 2.61B | |
-63.81% | 2.42B | |
-9.24% | 2.27B | |
+21.21% | 2.1B | |
-9.38% | 1.76B |